and the drug company shenanigans continue

I realize that I have blogged lots about drug company malfeasance/shenanigans. but they keep on coming and seem to be getting worse. here is another from the NY Times on  Daraprim (the brand name for pyrimethamine, a 62-year old drug used for parasitic infections, most notably for toxoplasmosis in HIV-infected patients but also occasionally for acute malaria) -- see http://www.nytimes.com/2015/09/21/business/a-huge-overnight-increase-in-a-drugs-price-raises-protests.html​ . [thanks to paul susman for bringing this to my attention]. issues:

--Turing pharmaceuticals just acquired the drug and "immediately raised the price to $750 a tablet from $13.50", though several years ago it was $1/pill. of note, "Daraprim's distribution is now tightly controlled, making it harder for generic companies to get the samples they need for the required testing".
--also, cycloserine (used to treat multi-drug resistant TB) was recently acquired by Rodelis Therapeutics, which increased the 30-day supply from $500 to $10,800
--the frequently-used antibiotic doxycycline went from $20/bottle in Oct 2013 to $1849 in April 2014
--and, from NPR's All-Things-Considered (see http://www.npr.org/sections/health-shots/2015/09/10/439219409/naloxone-price-soars-key-weapon-against-heroin-overdoses ), naloxone (Narcan, available since 1971), the main drug used to reverse potentially lethal opioid overdoses, is now a national focus in dealing with the opioid crisis (huge increases in the numbers of people trained to use it, large-scale programs to distribute and make free access to the intranasal form for opioid users, police, etc.) Injectable naloxone had been about $1/shot. The intranasal naloxone is made by only one company (Amphastar). NPR comments that in Baltimore, the price of naloxone in February of $20/dose jumped to $40/dose in July (thanks to sarah taylor for this reference).  
--and, speaking of opioids, though this is more an FDA and drug company joint shenanigans, oxycontin was just approved for kids over 11 years old (see http://www.nytimes.com/aponline/2015/08/13/us/politics/ap-us-oxycontin-children.html​  for the FDA press release and http://www.nytimes.com/2015/09/21/opinion/oxycontin-is-not-for-kids.html?emc=eta1 for an editorial). However, there are several studies finding that children are at a higher risk of addiction than adults (see blogs in http://blogs.bmj.com/ebm/category/pain/  and a USA Today articlehttp://www.usatoday.com/story/news/2015/08/14/fda-approves-oxycontin-kids/31711929/​ ). My feeling on this is that there are some small numbers of kids who need chronic opioids for pain control, that fentanyl patches are already available, and that oxycontin has such a long history of abuse/addiction and is already being abused by kids ("1 in 25 high school seniors has abused oxycontin" per the USA Today report, the number of prescription painkillers has quadrupled since 1999, and >44,000 Americans die of drug overdoses every year). so, seems to me that the risks far outweigh the benefits (except for Purdue Pharmaceuticals, which is undoubtedly laughing all the way to the bank....)

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

HDL a negative risk factor? or cholesterol efflux??

Although the data on HDL being protective of atherosclerotic disease is pretty consistent, there are negative studies, and the data on medications which dramatically improve HDL levels (eg, the cholesteryl ester transfer protein --CETP --inhibitors, such as torcetrapib) are clinically disappointing. there have been several explanations for this. for example, some HDL particles are "pro-inflammatory" and elicit an atherosclerotic response (which may be related to apolipoprotein C-III). a new article in NEJM highlights another angle -- that the issue is not the HDL number, but HDL's functionality in the reverse transport of cholesterol, as measured by the cholesterol efflux capacity (see  lipids HDL efflux capacity vs amt NEJM 2014 in dropbox, or  DOI: 10.1056/NEJMoa1409065). This article looks at the Dallas Heart Study, where they measured HDL levels, HDL particle concentrations, and cholesterol efflux capacity in 2924 adults free of cardiovascular disease and followed p
Read more

Drug company shenanigans: narcolepsy drug

I have not done a blog for a long time on drug company shenanigans. So it is my great pleasure to bring up a brand-new drug company approach to garner huge amounts of money (see  https://www.nytimes.com/2023/02/28/business/jazz-narcolepsy-avadel-patents.html?smid=nytcore-ios-share&referringSource=articleShare  ).  Based on an article by  Rebecca Robbins of the New York Times, who has written several articles on drug company excesses   As background, this will be my 42 nd  such blog: for the array, see  https://bucommunitymed.wpengine.com/page/4/?s=drug+company+shenanigans   Th e drug company  approach  this time  to extending  their  patents has a few “interesting” angles: -- this is a medication manufactured by Jazz Pharmaceuticals to treat narcolepsy: there are 2 versions: Xyrem and Xywav (Xywav has less sodium, so is marketed to those who should be on a low sodium diet). These meds are basically derivatives of gammahydroxybutyric acid (GHB)      -- the drug actually has a pretty
Read more

UPDATE: ASCVD risk factor critique

  I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:              -- there is very clear evidence that there are many individual risk factors that are associated with increased risk of a cardiovascu
Read more